Mergers and Acquisitions Review: ShangPharma might Go PRIVATE, Vivendi Wants RID Of Activision

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Shares of ShangPharma (NYSE:SHP) pop following word that a group of investors wants to take it private, offering $8.50 to $9.50 per ADS. A special committee is being created by which to evaluate the bid.

Don’t Miss: Are Facebook and Yahoo Forgetting Enmity?

TeleCommunication Systems (NASDAQ:TSYS) purchases microDATA GIS, which supplies next-generation 9-1-1 call-management procedures, at a price of $37 million, of which $20 million consists of up-front cash. An $80 million credit facility has been obtained by the buyer, whose existing E9-1-1 call-routing solutions current support more than half of all emergency calls.

Vivendi (VIVHY.PK) is seeking a buyer for its 61 percent investment in Activision (NASDAQ:ATVI), as was announced last week, and is said to be working with an investment bank for evaluation of the stake. Also reported is that the bankers are “sounding out” technology and media firms such as Tencent, Time Warner, and Microsoft, as well as private equity firms. The divestiture of the investment is crucial to Vivendi’s restructuring plans, but a finding a suitor for the $13.3 billion company could be problematic, and many observers believe that a spin-off is more likely.

Don’t Miss: Will Foxconn Build Amazon an iPhone KILLER?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business